Fig. 1From: Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockadeKaplan–Meier estimates of overall survival after CRPC stratified by achievement of 90% PSA reduction (PSA90) after treatment with enzalutamideBack to article page